Next Generation Allogeneic CAR-T And CAR-NK Therapies: Technologies, Platforms, And Commercialization Outlook

Table of Contents

Chapter 1. Overview of CAR-T and CAR-NK
                    1.1. Evolution from Autologous to Allogeneic
                    1.2. CAR-T vs CAR-NK: Comparative Analysis
                    1.3. Current Approved Autologous CAR-T Therapies
                    1.4. Clinical Trials Landscape
Chapter 2. Emerging Technologies and Innovations
                    2.1. Gene Editing Innovations
                    2.2. iPSC-Derived Universal Donor Platforms
                    2.3. Cytokine Armoring & Next-Gen CAR Constructs
                    2.4. Non-Viral Gene Delivery Approaches
                    2.5. Safety Mechanisms
Chapter 3. Commercialization Landscape
                    3.1. Key Commercialization Opportunities
                    3.2. Corporate Activity and Strategic Alliances
                    3.3. Innovation Hubs and Accelerators
Chapter 4. Challenges and Risk Factors
                    4.1. Manufacturing Scale & Process Complexity
                    4.2. Regulatory Scrutiny for Multiplex Editing
                    4.3. Competition from Next-Gen Modalities (TCR-T, bispecifics)
                    4.4. Reimbursement & Pricing Pressure for Cell Therapies